Patents by Inventor Kunihiro Kaihatsu
Kunihiro Kaihatsu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220251519Abstract: A concentration membrane for use in concentrating biological particles, including: a hydrophilic composite porous membrane including: a porous substrate; and a hydrophilic resin with which at least one main surface and inner surfaces of pores of the porous substrate are coated, the hydrophilic composite porous membrane having a ratio t/x of a membrane thickness t (m) to an average pore diameter x (m), as measured with a perm porometer, of from 50 to 630.Type: ApplicationFiled: January 28, 2020Publication date: August 11, 2022Applicants: TEIJIN LIMITED, VISGENE, LTD.Inventors: Mami NAMBU, Yoshikazu IKUTA, Yu NAGAO, Kunihiro KAIHATSU, Ikuko YUMEN, Katsuya OGATA, Daisuke AOKI
-
Patent number: 10577396Abstract: An object of the present invention is to conduct a search for a compound to be arranged at a terminal of a peptide nucleic acid effective in detecting a single nucleotide polymorphism. Provided is a tolan compound represented by the following formula (1): wherein R1 represents a phenyl group or a naphthyl group, the phenyl group may have 1 to 5 substituents that are identical to or different from each other, and the naphthyl group may have 1 to 7 substituents that are identical to or different from each other.Type: GrantFiled: September 16, 2016Date of Patent: March 3, 2020Assignee: Osaka UniversityInventors: Kunihiro Kaihatsu, Nobuo Kato, Kenji Takagi
-
Publication number: 20180258141Abstract: An object of the present invention is to conduct a search for a compound to be arranged at a terminal of a peptide nucleic acid effective in detecting a single nucleotide polymorphism. Provided is a tolan compound represented by the following formula (1): wherein R1 represents a phenyl group or a naphthyl group, the phenyl group may have 1 to 5 substituents that are identical to or different from each other, and the naphthyl group may have 1 to 7 substituents that are identical to or different from each other.Type: ApplicationFiled: September 16, 2016Publication date: September 13, 2018Inventors: Kunihiro KAIHATSU, Nobuo KATO, Kenji TAKAGI
-
Patent number: 9901565Abstract: The present invention provides a pharmaceutical composition that has excellent safety and targets a different step in the virus propagation cycle than conventional pharmaceutical compositions, applicable as an antiviral agent. A pharmaceutical composition containing an epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a salt thereof is prepared. This can be used as a membrane fusion inhibitor that inhibits viral membrane fusion. In the following formula, R1 to R6 are each a hydrogen atom, halogen, sodium, potassium, or a straight-chain or branched, saturated or unsaturated acyl group and may be identical to or different from one another. The acyl group may be substituted further with one or more substituents. At least one of R1 to R6 is the acyl group. R7 to R16 are each a hydrogen atom, halogen, sodium, or potassium and may be identical to or different from one another.Type: GrantFiled: December 23, 2014Date of Patent: February 27, 2018Assignee: Protectea, Ltd.Inventors: Kunihiro Kaihatsu, Shuichi Mori, Tomo Daidoji, Nobuo Kato, Shinya Miyake
-
Patent number: 9801850Abstract: The present invention provides an epigallocatechin gallate derivative (EGCG derivative) that has excellent safety and antibacterial properties. An epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a salt thereof is used as an antibacterial agent. In the formula, R1 to R6 are each a hydrogen atom, halogen, sodium, potassium, or a straight-chain or branched, saturated or unsaturated acyl group and may be identical to or different from one another. The acyl group may be substituted further with one or more substituents. At least one of the R1 to R6 is the acyl group. R7 to R16 are each a hydrogen atom, halogen, sodium, or potassium and may be identical to or different from one another.Type: GrantFiled: July 30, 2010Date of Patent: October 31, 2017Assignee: OSAKA UNIVERSITYInventors: Kunihiro Kaihatsu, Yoshimi Matsumoto
-
Publication number: 20150111961Abstract: The present invention provides a pharmaceutical composition that has excellent safety and targets a different step in the virus propagation cycle than conventional pharmaceutical compositions, applicable as an antiviral agent. A pharmaceutical composition containing an epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a salt thereof is prepared. This can be used as a membrane fusion inhibitor that inhibits viral membrane fusion. In the following formula, R1 to R6 are each a hydrogen atom, halogen, sodium, potassium, or a straight-chain or branched, saturated or unsaturated acyl group and may be identical to or different from one another. The acyl group may be substituted further with one or more substituents. At least one of R1 to R6 is the acyl group. R7 to R16 are each a hydrogen atom, halogen, sodium, or potassium and may be identical to or different from one another.Type: ApplicationFiled: December 23, 2014Publication date: April 23, 2015Inventors: Kunihiro KAIHATSU, Shuichi MORI, Tomo DAIDOJI, Nobuo KATO, Shinya MIYAKE
-
Patent number: 8952055Abstract: The present invention provides a pharmaceutical composition that has excellent safety and targets a different step in the virus propagation cycle than conventional pharmaceutical compositions, applicable as an antiviral agent. A pharmaceutical composition containing an epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a salt thereof is prepared. This can be used as a membrane fusion inhibitor that inhibits viral membrane fusion. In the following formula, R1 to R6 are each a hydrogen atom, halogen, sodium, potassium, or a straight-chain or branched, saturated or unsaturated acyl group and may be identical to or different from one another. The acyl group may be substituted further with one or more substituents. At least one of R1 to R6 is the acyl group. R7 to R16 are each a hydrogen atom, halogen, sodium, or potassium and may be identical to or different from one another.Type: GrantFiled: February 2, 2009Date of Patent: February 10, 2015Assignee: Protectea, Ltd.Inventors: Kunihiro Kaihatsu, Shuichi Mori, Tomo Daidoji, Nobuo Kato, Shinya Miyake
-
Publication number: 20120136049Abstract: The present invention provides an epigallocatechin gallate derivative (EGCG derivative) that has excellent safety and antibacterial properties. An epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a salt thereof is used as an antibacterial agent. In the formula, R1 to R6 are each a hydrogen atom, halogen, sodium, potassium, or a straight-chain or branched, saturated or unsaturated acyl group and may be identical to or different from one another. The acyl group may be substituted further with one or more substituents. At least one of the R1 to R6 is the acyl group. R7 to R16 are each a hydrogen atom, halogen, sodium, or potassium and may be identical to or different from one another.Type: ApplicationFiled: July 30, 2010Publication date: May 31, 2012Applicant: OSAKA UNIVERSITYInventors: Kunihiro Kaihatsu, Yoshimi Matsumoto
-
Publication number: 20110003889Abstract: The present invention provides a pharmaceutical composition that has excellent safety and targets a different step in the virus propagation cycle than conventional pharmaceutical compositions, applicable as an antiviral agent. A pharmaceutical composition containing an epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a salt thereof is prepared. This can be used as a membrane fusion inhibitor that inhibits viral membrane fusion. In the following formula, R1 to R6 are each a hydrogen atom, halogen, sodium, potassium, or a straight-chain or branched, saturated or unsaturated acyl group and may be identical to or different from one another. The acyl group may be substituted further with one or more substituents. At least one of R1 to R6 is the acyl group. R7 to R16 are each a hydrogen atom, halogen, sodium, or potassium and may be identical to or different from one another.Type: ApplicationFiled: February 2, 2009Publication date: January 6, 2011Inventors: Kunihiro Kaihatsu, Shuichi Mori, Tomo Daidoji, Nobuo Kato, Shinya Miyake